Usa security bill Investigations Markets Sustainability Usa

Eli Lilly and Company’s Tirzepatide GLP-1 Weight Loss Drug Is Now Poised To Shrink the Market for Breathing Machines

wccftech.com

This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.

What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)?

This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that.

Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2.

To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on sleep apnea.

Все новости дня

This page might use cookies if your analytics vendor requires them.